MedPath

Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis

Completed
Conditions
Peritonitis
Interventions
Biological: blood samples
Registration Number
NCT04126577
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. Phospholipid transfer protein (PLTP) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination.

The objective of this study is to study the relationship between PLTP and the elimination of bacterial toxins in humans. A better understanding of the elimination of these toxins will lead to a better understanding of the disease. The ultimate objective is to improve the management of intra-abdominal infections.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • person who has given oral consent (patient or family member)
  • pre-operative SEPSIS criteria (qSOFA >=2) or vasopressor or mechanical ventilation treatment
  • admitted to the operating room for suspected generalized secondary peritonitis
Exclusion Criteria
  • person not affiliated to national health insurance
  • person under legal protection (curatorship, guardianship)
  • person under court order
  • pregnant, parturient or breastfeeding woman
  • minor
  • immunosuppression (HIV infection, corticosteroid treatment > 0.15 mg/kg/day prednisolone equivalent > 2 weeks, immunosuppressive treatment, primary cellular immune deficiency)
  • decision to limit or stop therapy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with suspected peritonitisblood samplesSecondary peritonitis, sepsis and endotoxemia
Primary Outcome Measures
NameTimeMethod
Perioperative plasma concentration in 3HM24 hours postoperatively
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Dijon Bourogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath